Sign In
Buy CANF
$3.12
+0.0100 (+0.322%)
At Close: Jun 03, 2026
Growing momentum for RAS inhibition at ASCO highlights Namodenoson's RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioP
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that ad
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
07:00am, Wednesday, 13'th May 2026
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies Ramat Gan, Israel, May 13, 2026 (GLOBE
Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small mole
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a bio
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targ
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
07:47am, Tuesday, 17'th Mar 2026
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE Americ
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
10:21am, Thursday, 05'th Mar 2026
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
10:25am, Wednesday, 04'th Mar 2026
RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a biotechnology company advancing a pipeline of propriet
Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study
10:07am, Wednesday, 04'th Mar 2026
Can-Fite BioPharma Ltd. (AMEX: CANF) shares are up on Wednesday following the company's announcement that its drug, Namodenoson, successfully met the primary endpoint in a Phase 2a study for pretreate
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
07:00am, Wednesday, 04'th Mar 2026
Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small mole
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
07:00am, Monday, 09'th Feb 2026
Namodenoson's oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
07:00am, Thursday, 05'th Feb 2026
Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Failure Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: C
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
07:00am, Tuesday, 20'th Jan 2026
Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026 Ramat Gan, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF)
